Pure Global
NCT06245421

Evaluation of the Efficacy and Safety of DM934 Versus Théalose on Eye Dryness

Multicentric, Randomized, Comparative Clinical Study on the Evaluation of the Efficacy and Safety of DM934 Versus Théalose on the Treatment of Moderate to Severe Ocular Dryness
Horus Pharma·ClinicalTrials.gov·device·Device trialRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Dry Eye
Drug/Device/Intervention
DM934
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Horus Pharma
Location
Aix-en-Provence,Bordeaux,Gdańsk,Valladolid,London, France,Poland,Spain,United Kingdom
Timeline & enrollment
Phase
N/A
Start date
Mar 07, 2024
End date
Dec 01, 2024
Enrollment
80 participants
Primary outcome

Cornea and conjunctiva staining (Oxford score)

Summary

This study is a multicentric, comparative, randomized, investigator-blinded, parallel group
 study to demonstrate the non-inferiority of DM934 in comparison with Théalose in terms of
 cornea and conjunctiva staining (Oxford score) on patients with moderate to severe ocular
 dryness, after 35 days of treatment

ICD-10 classifications
Ocular painAvulsion of eyeOther corneal deformitiesCorneal ulcerDry mouth, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06245421
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06245421 through Pure Global AI's free database. This phase not specified trial is sponsored by Horus Pharma and is currently Recruiting. The study focuses on Dry Eye. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.